Seres Plans Deep Dive After Microbiome Drug Fails In Ulcerative Colitis Trial

22 Jul 2021

The company plans an intensive review to determine the path forward for SER-287. A similar deep dive led to the successful revival of its C. difficile drug, SER-109, which it plans to submit for approval.

Bacterias 3D rendering — Seres will do a deep dive into data from its failed Phase IIb study of SER-287 in ulcerative colitis • Source: Shutterstock

Seres Therapeutics, Inc.’s plans for its microbiome drug SER-287 are unclear following the failure of a Phase IIb study in ulcerative colitis (UC), but the company will take a close look at the results to help determine SER-287’s future or provide learnings for its next-generation UC candidate, SER-301.

Seres similarly did a deep dive into a failed Phase II study of its recurrent Clostridium difficile infection (rCDI) drug,...